Neurotrophic Tyrosine Receptor Kinase Fusion (NTRK)


Neurotrophic tyrosine receptor kinase fusion, or NTRK, has emerged in the last six years as a rare, but targetable alteration in several cancers. Dr. Herbert Loong, clinical assistant professor in the department of clinical oncology and deputy medical director of the Phase 1 Clinical Trials Center of The Chinese University of Hong Kong, joins Lung Cancer Considered host Dr. Stephen Liu to discuss NTRK and what impact it may have on lung cancer research and treatment.

Stephen Liu, MD
Stephen Liu


Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Herbert Loong
Herbert H. Loong
Associate Professor
Department of Clinical Oncology Deputy Medical Director – Phase 1 Clinical Trials Centre